

AD-A242 097



AD _____

Vign
②

COMPARATIVE INFECTIVITY DETERMINATION OF DENGUE VIRUS VACCINE
CANDIDATES IN RHESUS MONKEYS, MOSQUITOES, AND CELL CULTURE

ANNUAL REPORT

EDMUNDO KRAISELBURD

AUGUST 28, 1991

DTIC
ELECTE
OCT 31 1991
S C D

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21702-5012

Contract No. DAMD17-89-C-9175

University of Puerto Rico
G.P.O. Box 5067
San Juan, Puerto Rico 00936

Approved for public release; distribution unlimited.

The findings in this report are not to be construed as an
official Department of the Army position unless so designated
by other authorized documents

91-14303



91 10 28 093

August 28, 1991

Annual

1 Sep 89 - 31 Aug 91

Comparative Infectivity Determination of Dengue Virus
Vaccine Candidates in Rhesus Monkeys, Mosquitoes, and
Cell Culture

DAMD17-89-C-9175

Edmundo Kraiselburd

63002A
3M263002D810 AA
DA335475

University of Puerto Rico
G.P.O. Box 5067
San Juan, Puerto Rico 00936

U.S. Army Medical Research & Development Command
Fort Detrick
Frederick, Maryland 21702-5012

Approved for public release; distribution unlimited

RA 1; Dengue virus; Vaccines; Infectivity; Rhesus monkeys;
Mosquitoes; Lab animals

Unclassified

Unclassified

Unclassified

Unlimited

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to **stay within the lines to meet optical scanning requirements.**

Block 1. Agency Use Only (Leave Blank)

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Names(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of ..., To be published in When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement.

Denote public availability or limitation. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR)

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - DOD - Leave blank

DOE - DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports

NASA - NASA - Leave blank

NTIS - NTIS - Leave blank.

Block 13. Abstract. Include a brief (Maximum 200 words) factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code (NTIS only).

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

Evaluation of Dengue-2 vaccines:

I DEN-2 S16803 STRAIN

On September 4, 1990, sixteen rhesus monkeys were sent from the Caribbean Primate Center (Sábana Seca) to the Animal Resources Facilities at the Medical Sciences Campus. The monkeys were bled on September 4, and on September 17, and the sera were stored at -20°C . The Plaque Reduction Neutralization test (PRNT), and the hemagglutination inhibition (HI) tests were performed using these serum samples (Pre-vaccination bleds).

The PRNT was performed using LLC-MK2 cells (sent by Dr. Goro Kuno CDC, San Juan Laboratories) grown in multiwell plates as described before (see Second Semi-Annual Report, August 31, 1990).

Vaccines and the other materials were received on 10/4/90 from Dr. Kenneth Eckels (Walter Reed Army Institute of Research).

The following vaccines of dengue 2 were received: PDK-10, PDK-20, PDK-30 and PDK-50.

On October 15, 1990 groups of four monkeys were inoculated s.c. with 0.5 ml of each candidate vaccine. The titration of the four vaccine candidates were made on the same day of inoculation using LLC-MK2 cells.

Vaccine titers obtained were as follows:

<u>Vaccine</u>	<u>LLC-MK2</u> <u>(Pfu/ml)</u>
PDK 10	7.65×10^5
PDK 20	4.35×10^5
PDK 30	4.20×10^5
PDK 50	1.16×10^6

Accession For	
VIS GRAB	<input checked="" type="checkbox"/>
SP1 TAB	<input type="checkbox"/>
Unprocessed	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

As stated above, all animals were vaccinated with 0.5 ml of above vaccines, with the exception of PDK-50 (that was diluted 1:7 before inoculation, as instructed by Dr. Eckels). Diluent used was sent by WRAIR.

After vaccination, animals were bled for 10 consecutive days. As agreed, these samples were sent to WRAIR for viremia studies. On days 30 and 60 post vaccination (Nov. 14, and December 12, 1990) animals were bled and PRNTs against Dengue-2 (NGC strain) and Dengue-2 (S16803), were performed.

Results of these tests are presented in Tables I & II (enclosed).

TABLE I
ANTIBODY RESPONSE OF MONKEYS INOCULATED WITH DIFFERENT DEN-2
VACCINE CANDIDATES

Monkey No.	Vaccine	Vaccine Innoculum Pfu/.5ml	N. Antibody Titers* day 30 day 60	
	PDK-10	3.8×10^5		
R04			110	>640
R09			260	320
R17			>640	>640
R30			640	110
	PDK-20	2.18×10^5		
R02			580	>640
R19			600	460
R49			>640	>640
R54			>640	>640
	PDK-30	2.1×10^5		
R11			160	350
R18			<10	<10
R21			>640	300
R37			160	140
	PDK-50	0.83×10^5		
R05			32	140
R08			39	>640
R15			100	350
R36			>640	>640

*Neutralizing antibodies titers were obtained by the PRNT test, using the NGC strain of DEN-2.

TABLE II

ANTIBODY RESPONSE OF MONKEYS INOCULATED WITH DIFFERENT DEN-2
VACCINE CANDIDATES

Monkey No.	Vaccine	Vaccine Innoculum Pfu/.5ml	N. Antibody Titers*	
			day 30	day 60
	PDK-10	3.8×10^5		
R04			340	640
R09			560	400
R17			600	580
R30			500	500
	PDK-20	2.18×10^5		
R02			>640	700
R19			>640	>640
R49			>1280	>640
R54			>1280	>1280
	PDK-30	2.1×10^5		
R11			>640	160
R18			<10	<10
R21			>640	>640
R37			>640	460
	PDK-50	$.83 \times 10^5$		
R05			64	94
R08			155	>640
R15			160	82
R36			640	>640

*Virus used for PRNT: Parent S16803 STRAIN

II Dengue-2 S16681 STRAIN:

On February 12, 1991, sixteen rhesus monkeys were sent from the Caribbean Primate Center (Sábana Seca) to the Animal Resources Facilities at the Medical Sciences Campus. The monkeys were bled on February 12, and on February 26, and the sera were stored at -20°C . The Plaque Reduction Neutralization test (PRNT) and the hemagglutination inhibition (HI) test were performed using these serum samples (Pre vaccination bleeds).

The PRNT was performed using LLC-MK2 cells (sent by Dr. Goro Kuno CDC, San Juan Laboratories) grown in multiwell plates as described before.

Vaccines and the other materials were received on 4/4/91 from Dr. Kenneth Eckels (Walter Reed Institute of Research).

The following vaccines of dengue 2 (strain S16681) including the parent seed were received: PDK-11, PDK-40 and PDK 53.

On April 22, 1991 groups of four monkeys were inoculated s.c. with 0.5 ml of each candidate vaccine. The titration of the four vaccine candidates were made on the same day of inoculation using LLC-MK2 cells.

Vaccine titers obtained were as follows:

<u>Vaccine</u>	<u>LLC-MK2 (CDC)</u> (Pfu/ml)	Titers reported by WRAIR (Pfu/0.2 ml)
S16681	3.3×10^7	1.8×10^6
PDK 11	7.9×10^6	4×10^6
PDK 40	2.2×10^5	2.2×10^5
PDK 53	3.3×10^4	2.2×10^5

Shown on the right column are the titers obtained at WRAIR. These titers were different to those obtained in our laboratory, using LLC-MK2 cells received from the local CDC laboratory. Very small plaques were observed with PDK 40 and 53. PDK 11 and the parent seed S16681 had approximately the same plaque size.

As stated above, all animals were vaccinated with 0.5 ml of above vaccines, with the exception of PDK-11 (that was diluted 1:18) and the parent seed (that was diluted 1:8) as previously agreed, before inoculation. Diluent used was sent by WRAIR.

After vaccination, animals were bled for 14 consecutive days. As agreed, these samples were sent to WRAIR for viremia studies. On days 30 and 58 post vaccination (May 22, and June 20, 1991) animals were bled and PRNTs against Dengue-2 (S16681 strain) were performed.

Results of these tests are presented in Table III (enclosed).

Future plans: Future plans call for the evaluation of other Dengue vaccine candidates, as described in the original application.

Man hours incurred: As described on original application for this time period.

Edmundo Kraiselburd, Ph.D.

Edmundo Kraiselburd, Ph.D.
Professor and Principal Investigator

TABLE III

ANTIBODY RESPONSE OF MONKEYS INOCULATED WITH DIFFERENT
DEN-2 (S16681) VACCINE CANDIDATES

Monkey No.	Vaccine	Vaccine Innoculum Pfu/0.5ml	N. Antibody Titers*	
			day 30 GMT	day 60 GMT
	S16681	2×10^6	1838	≥ 4608
R25			1250	4800
R13			2560	5200
R50			2300	3500
H5			1550	>5120
	PDK11	2.2×10^5	1267	≥ 4104
J15			800	4100
R28			1280	2700
R41			1800	5000
J16			1400	>5120
	PDK40	1.1×10^5	338	1652
J21			560	2560
R35			260	2000
J20			150	470
J22			600	3100
	PDK53	1.60×10^4	323	1290
R6			640	4300
R16			330	1120
R1			270	900
R38			190	640

*Virus used for PRNT: Parent seed S16681 STRAIN
GMT = Geometric mean titer